Imugene Ltd (ASX:IMU) will present the updated patient data from its phase 1b study of HER-Vaxx cancer vaccine at the prestigious American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
The abstract will be presented by Dr Yee Chao, director of the Department of Oncology at the Veterans General Hospital in Taipei, Taiwan and a lead investigator in the phase 1b study.
Dr Chao’s presentation will be featured at the ASCO Gastrointestinal (Non-colorectal) Cancer Session on Monday June 3, 2019 between 8:00 am and 11:00 am.
READ: Imugene well-funded to progress clinical milestones
It is worth noting that Imugene’s phase 1b HER-Vaxx study which completed enrolment in 2018 has met all its primary endpoints.
The study is ongoing with patients continuing to receive HER-Vaxx every 3 months to maintain high levels of cancer targeting antibodies. A phase 2 study was initiated in March 2019.
ASCO presentation
Imugene’s ASCO presentation is entitled: ‘A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.’
The ASCO annual meeting attracts more than 40,000 cancer specialists and is one of the largest educational and scientific events in the oncology community where the latest research and clinical results are highlighted.
Imugene managing director and chief executive officer Leslie Chong said: “There is continued interest in the positive data from our Phase 1b trial which clearly supports our B-cell platform cancer vaccine strategy for treating HER-2 positive gastric cancer.”
Imugene’s HER-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.
The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER-2/neu.
It has been shown in pre-clinical studies and now in phase I studies to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.